discussions regarding intra-and inter-institutional vaccine goals, but also to provide a common language for determining priority areas of national and global interests. Appreciating the trade-offs inherent in priority setting exercises may well serve to motivate and focus new vaccine development.
The value of SMART Vaccines will depend, in part, on data that need to be generated as candidate vaccines evolve and as disease epidemiology becomes better characterized in different parts of the world. In the future (beyond Phase II), an active community of users and an open-source environment could likely lead to enhancement of the software’s capabilities through creation and sharing of databases for populations from different countries, generation of data collection templates, refinement of the attributes and the attribute selection process, enhancement of validation tools and the user interface, and other ways to address the risk and uncertainty surrounding the characterization of vaccines that have not yet been developed. This study is the first step in moving toward these goals.